Kratom: The Supplement That Will Kill Godzilla

By Josh Bloom — Jan 13, 2016
Federal Marshals just seized 90,000 bottles of kratom, another so-called dietary supplement produced by an Illinois company. It's a hallucinogenic narcotic, so what exactly is it supposed to supplement? The LSD you took as a teenager? Once again, this nonsense is made possible by Utah Sen. Orrin Hatch and the insane legislation he co-authored in 1994.

Federal Marshals just seized 90,000 bottles of kratom, another so-called dietary supplement produced by an Illinois company. It's a hallucinogenic narcotic, so what exactly is it supposed to supplement? The LSD you took as a teenager? Once again, this nonsense is made possible by Utah Sen. Orrin Hatch and the insane legislation he co-authored in 1994.

Body Mass History May Weigh In on Mortality Risk

By Ruth Kava — Jan 13, 2016
Although we know that obesity is associated with an increased risk of numerous ills, it hasn't been clear that it's also linked to an increased risk of death. A new study suggests that the way the BMI data has been examined may account for that dissonance, and that body weight history may also weigh in on mortality risk.

Although we know that obesity is associated with an increased risk of numerous ills, it hasn't been clear that it's also linked to an increased risk of death. A new study suggests that the way the BMI data has been examined may account for that dissonance, and that body weight history may also weigh in on mortality risk.

Charlie Sheen's Medical Madness & Other Celebrity Idiots

By Josh Bloom — Jan 13, 2016
In an act of sheer brilliance, Charlie Sheen stopped taking his AIDS meds and surprise! his viral load went up. Then other similarly-enlightened celebs chimed in. Who looked most foolish? We think Jenny McCarthy dispensing advice in some tongue that barely resembled English made her top boob.

In an act of sheer brilliance, Charlie Sheen stopped taking his AIDS meds and surprise! his viral load went up. Then other similarly-enlightened celebs chimed in. Who looked most foolish? We think Jenny McCarthy dispensing advice in some tongue that barely resembled English made her top boob.

Hasta la Vista Infertility?

By Lila Abassi — Jan 13, 2016
It may soon be the time to say farewell to sluggish, slipshod and sub-par sperm. Scientists in Germany have created the ultimate superhero armor for even the laziest reproductive soldiers, and they can even benefit from artificial propulsion.

It may soon be the time to say farewell to sluggish, slipshod and sub-par sperm. Scientists in Germany have created the ultimate superhero armor for even the laziest reproductive soldiers, and they can even benefit from artificial propulsion.

Obama's Cancer 'Moonshot': A Shot in the Dark

By Gil Ross — Jan 13, 2016
President Obama declared that the U.S. will mount a new, extraordinary fight against cancer, with the aim of finally "curing it once and for all." Unfortunately, this is an impossible task. Throwing money at this disease will aid some researchers but this new initiative will speed progress only slightly, if at all.

President Obama declared that the U.S. will mount a new, extraordinary fight against cancer, with the aim of finally "curing it once and for all." Unfortunately, this is an impossible task. Throwing money at this disease will aid some researchers but this new initiative will speed progress only slightly, if at all.

18 Million Youngsters See E-Cigarette Ads Which Worries the CDC

By Hank Campbell — Jan 13, 2016
Over 18 million young people 68.9 percent of middle and high school students see some form of e-cigarette advertising, according to the CDC. The agency is worried about e-cig use in teens, and officials there are right in their concern. But is it an advertising-created phenomenon?

Over 18 million young people 68.9 percent of middle and high school students see some form of e-cigarette advertising, according to the CDC. The agency is worried about e-cig use in teens, and officials there are right in their concern. But is it an advertising-created phenomenon?

'Right to Try' When Hope Dims, the Case for Unproven Drugs

By Lila Abassi — Jan 12, 2016
If it s a desperate race against time, and there's a possible life-saving therapy that hasn't undergone the rigorous FDA approval process, should an unapproved drug be used in the chance that it may prove effective, or life saving? Here's the case for the Right to Try.

If it s a desperate race against time, and there's a possible life-saving therapy that hasn't undergone the rigorous FDA approval process, should an unapproved drug be used in the chance that it may prove effective, or life saving? Here's the case for the Right to Try.

Revisiting Chemical Dumping to Call Again for TSCA 'Reform'

By Gil Ross — Jan 12, 2016
PFOA, a chemical used to make non-stick substances, was dumped into the Ohio River between the 1950s and 1990s. A New York Times Magazine article serves as an expose of this practice, targeting DuPont as a bad actor. The newspaper uses this as an excuse to call for revision of federal government legislation.

PFOA, a chemical used to make non-stick substances, was dumped into the Ohio River between the 1950s and 1990s. A New York Times Magazine article serves as an expose of this practice, targeting DuPont as a bad actor. The newspaper uses this as an excuse to call for revision of federal government legislation.

Breast Cancer Screening Lowers Mortality, Yet Questions Remain

By ACSH Staff — Jan 12, 2016
When should women at average risk for breast cancer start mammography screenings? Should they start at 40, or is it better to wait until 50? The U.S. Preventive Services Task Force has weighed in, concluding that "cancer mortality is generally reduced" with screening. But other issues need answers.

When should women at average risk for breast cancer start mammography screenings? Should they start at 40, or is it better to wait until 50? The U.S. Preventive Services Task Force has weighed in, concluding that "cancer mortality is generally reduced" with screening. But other issues need answers.

Treating Liver Cirrhosis Focuses on New Target

By Lila Abassi — Jan 12, 2016
A protein involved in pathological angiogenesis can serve as a new therapeutic target in the treatment of chronic liver disease, which claims nearly 50,000 lives annually. In vivo tests involving knock-out mice has shown promising results.

A protein involved in pathological angiogenesis can serve as a new therapeutic target in the treatment of chronic liver disease, which claims nearly 50,000 lives annually. In vivo tests involving knock-out mice has shown promising results.